If approved, tofersen would be the first treatment to target a genetic cause of ALS, albeit one ... by 25 January, and Biogen will also have to make the case for its drug at an advisory committee ...

Due to increased competitive pressure, sales of the Biogen drug have declined almost 3% year ... 1 amyotrophic lateral sclerosis (SOD1-ALS). Qalsody was also approved for a similar indication ...

Also Read: Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest ... including programs for ALS, tremor, and Angelman syndrome. Two promising late-stage programs, felzartamab ...

TOKYO -- New treatments for ALS are progressing little by little, with companies like U.S.-based Biogen and Japan's Otsuka Pharmaceutical working to give hope to patients of the incurable disease.

and ALS drug tofersen. Although Biogen faced an even tougher commercial environment for its multiple sclerosis portfolio outside of leading drug Ocrevus than we had expected in the quarter ...

Speaking of Sage, news broke recently of an unsolicited buyout offer of $7.22 a share from Biogen that was rejected. To my mind, this speaks to the promise they see in this drug and the team at ...

Japanese firm Mitsubishi Tanabe's Radicava, generic drug Riluzole, and Biogen's (BIIB.O), opens new tab Qalsody are some of the FDA approved ALS treatments available in the U.S. Shares of New ...

Japanese firm Mitsubishi Tanabe's Radicava, generic drug riluzole, and Biogen's (BIIB.O), opens new tab Qalsody are some of the FDA approved ALS treatments available in the U.S. Complete results ...